Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine

Mitchell B. Cohen, Ralph A. Giannella, Judy Bean, David N. Taylor, Susan Parker, Amy Hoeper, Stephen Wowk, Jennifer Hawkins, Sims K. Kochi, Gilbert Schiff, Kevin P. Killeen

Research output: Contribution to journalArticle

Abstract

Peru-15 is a live attenuated oral vaccine derived from a Vibrio cholerae O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 × 108 CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 105 CFU of virulent V. cholerae O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98% showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42%) of the 12 placebo recipients and none (0%) of the 24 vaccinees had moderate or severe diarrhea (≥3,000 g of diarrheal stool) (P = 0.002; protective efficacy, 100%; lower one-sided 95% confidence limit, 75%). A total of 7 (58%) of the 12 placebo recipients and 1 (4%) of the 24 vaccinees had any diarrhea (P <0.001; protective efficacy, 93%; lower one-sided 95% confidence limit, 62%). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool V. cholerae excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.

Original languageEnglish (US)
Pages (from-to)1965-1970
Number of pages6
JournalInfection and Immunity
Volume70
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Cholera Vaccines
Cholera
Placebos
Volunteers
Diarrhea
Safety
Vibrio cholerae O1
Buffers
Vaccines
Attenuated Vaccines
Vibrio cholerae
Vaccination
Fever
Peru 15
Weights and Measures
Antibodies
DNA
Incidence

ASJC Scopus subject areas

  • Immunology

Cite this

Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. / Cohen, Mitchell B.; Giannella, Ralph A.; Bean, Judy; Taylor, David N.; Parker, Susan; Hoeper, Amy; Wowk, Stephen; Hawkins, Jennifer; Kochi, Sims K.; Schiff, Gilbert; Killeen, Kevin P.

In: Infection and Immunity, Vol. 70, No. 4, 2002, p. 1965-1970.

Research output: Contribution to journalArticle

Cohen, MB, Giannella, RA, Bean, J, Taylor, DN, Parker, S, Hoeper, A, Wowk, S, Hawkins, J, Kochi, SK, Schiff, G & Killeen, KP 2002, 'Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine', Infection and Immunity, vol. 70, no. 4, pp. 1965-1970. https://doi.org/10.1128/IAI.70.4.1965-1970.2002
Cohen, Mitchell B. ; Giannella, Ralph A. ; Bean, Judy ; Taylor, David N. ; Parker, Susan ; Hoeper, Amy ; Wowk, Stephen ; Hawkins, Jennifer ; Kochi, Sims K. ; Schiff, Gilbert ; Killeen, Kevin P. / Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. In: Infection and Immunity. 2002 ; Vol. 70, No. 4. pp. 1965-1970.
@article{bfacca101e8b441c8128d12bbe6e09c6,
title = "Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine",
abstract = "Peru-15 is a live attenuated oral vaccine derived from a Vibrio cholerae O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 × 108 CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 105 CFU of virulent V. cholerae O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98{\%} showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42{\%}) of the 12 placebo recipients and none (0{\%}) of the 24 vaccinees had moderate or severe diarrhea (≥3,000 g of diarrheal stool) (P = 0.002; protective efficacy, 100{\%}; lower one-sided 95{\%} confidence limit, 75{\%}). A total of 7 (58{\%}) of the 12 placebo recipients and 1 (4{\%}) of the 24 vaccinees had any diarrhea (P <0.001; protective efficacy, 93{\%}; lower one-sided 95{\%} confidence limit, 62{\%}). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool V. cholerae excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.",
author = "Cohen, {Mitchell B.} and Giannella, {Ralph A.} and Judy Bean and Taylor, {David N.} and Susan Parker and Amy Hoeper and Stephen Wowk and Jennifer Hawkins and Kochi, {Sims K.} and Gilbert Schiff and Killeen, {Kevin P.}",
year = "2002",
doi = "10.1128/IAI.70.4.1965-1970.2002",
language = "English (US)",
volume = "70",
pages = "1965--1970",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine

AU - Cohen, Mitchell B.

AU - Giannella, Ralph A.

AU - Bean, Judy

AU - Taylor, David N.

AU - Parker, Susan

AU - Hoeper, Amy

AU - Wowk, Stephen

AU - Hawkins, Jennifer

AU - Kochi, Sims K.

AU - Schiff, Gilbert

AU - Killeen, Kevin P.

PY - 2002

Y1 - 2002

N2 - Peru-15 is a live attenuated oral vaccine derived from a Vibrio cholerae O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 × 108 CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 105 CFU of virulent V. cholerae O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98% showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42%) of the 12 placebo recipients and none (0%) of the 24 vaccinees had moderate or severe diarrhea (≥3,000 g of diarrheal stool) (P = 0.002; protective efficacy, 100%; lower one-sided 95% confidence limit, 75%). A total of 7 (58%) of the 12 placebo recipients and 1 (4%) of the 24 vaccinees had any diarrhea (P <0.001; protective efficacy, 93%; lower one-sided 95% confidence limit, 62%). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool V. cholerae excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.

AB - Peru-15 is a live attenuated oral vaccine derived from a Vibrio cholerae O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 × 108 CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 105 CFU of virulent V. cholerae O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98% showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42%) of the 12 placebo recipients and none (0%) of the 24 vaccinees had moderate or severe diarrhea (≥3,000 g of diarrheal stool) (P = 0.002; protective efficacy, 100%; lower one-sided 95% confidence limit, 75%). A total of 7 (58%) of the 12 placebo recipients and 1 (4%) of the 24 vaccinees had any diarrhea (P <0.001; protective efficacy, 93%; lower one-sided 95% confidence limit, 62%). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool V. cholerae excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.

UR - http://www.scopus.com/inward/record.url?scp=0036128729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036128729&partnerID=8YFLogxK

U2 - 10.1128/IAI.70.4.1965-1970.2002

DO - 10.1128/IAI.70.4.1965-1970.2002

M3 - Article

C2 - 11895960

AN - SCOPUS:0036128729

VL - 70

SP - 1965

EP - 1970

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 4

ER -